Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

被引:0
作者
Freyja Aichholzer
Hans-Wolfgang Klafki
Isabella Ogorek
Jonathan Vogelgsang
Jens Wiltfang
Norbert Scherbaum
Sascha Weggen
Oliver Wirths
机构
[1] University Medical Center (UMG),Department of Psychiatry and Psychotherapy
[2] Georg-August-University,Department of Neuropathology
[3] Heinrich-Heine-University,Neurosciences and Signaling Group, Department of Medical Sciences, Institute of Biomedicine (ibiMED)
[4] University of Aveiro,LVR
[5] German Center for Neurodegenerative Diseases (DZNE),Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty
[6] University of Duisburg-Essen,undefined
来源
Alzheimer's Research & Therapy | / 13卷
关键词
Alzheimer’s disease; GPNMB; Cerebrospinal fluid; Biomarker; Inflammation; Immunoassay;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 588 条
[1]  
Querfurth HW(2020)Alzheimer’s disease facts and figures Alzheimers Dement 2020 391-460
[2]  
LaFerla FM(2010)Alzheimer’s disease New Engl J Med 362 329-344
[3]  
Nhan HS(2015)The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes Acta Neuropathol 129 1-19
[4]  
Chiang K(2015)Tau aggregation and its interplay with amyloid-beta Acta Neuropathol 129 207-220
[5]  
Koo EH(2018)Current state of Alzheimer’s fluid biomarkers Acta Neuropathol 136 821-853
[6]  
Nisbet RM(2016)CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis Lancet Neurol 15 673-684
[7]  
Polanco JC(2017)CSF Aβ1–42 – an excellent but complicated Alzheimer’s biomarker – a route to standardisation Clin Chim Acta 467 27-33
[8]  
Ittner LM(2018)Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry World J Biol Psychiatry 19 244-328
[9]  
Gotz J(2014)Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography JAMA Neurol 71 1282-1289
[10]  
Molinuevo JL(2017)Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment JAMA Neurol 74 1492-1501